27 Sept

A post hoc analysis of the EYLEA VIEW 1 and VIEW 2 studies found more frequent dosing improved Wet AMD early persistent retinal fluid outcomes at 52 weeks as measured by fluid status and visual acuity.1

Read more about the results

27 Sept

Look for Regeneron Booth #4239 at the American Academy of Ophthalmology (AAO) annual meeting at the Ernest N. Morial Convention Center in New Orleans, LA, November 11-14, 2017.

Read more about the meeting

27 Sept
27 Sept
See Life In My Eyes
In My Eyes by Regeneron logo

A powerful teaching tool to use with patients and caregivers, this unique app lets the user experience common symptoms of certain retinal diseases (e.g., blind spots, blurriness, and wavy lines) in a 360° view. In My Eyes features virtual reality/augmented reality to show the impact of vision impairment on everyday situations.

Download the free app on iOS or Android now.

27 Sept
27 Sept
Educational Webinar Series on Coordinated Care Organizations (CCOs) Sponsored by Regeneron

This prerecorded, 3-part webinar series focuses on the emerging role of CCOs. Coordinated care is the patient-oriented alignment of healthcare services across providers. The series helps healthcare professionals (HCPs) and practice managers understand CCOs and evaluate and respond to their management of anti–vascular endothelial growth factor (anti-VEGF) treatments, including EYLEA. As CCOs take on responsibility for the cost of care and drugs from payers, they are instituting management tools that can restrict HCP choice. Distinctions between CCO management and payer management of anti-VEGF treatment choices will be discussed.

  • Part 1 – Understanding CCOs 29:25
  • Part 2 – Evaluating CCO Management of Anti-VEGF Treatments 26:38
  • Part 3 – Responding to CCO Challenges to Access 27:48
  • Each webinar will be approximately 30 minutes including Q & A.
Important Safety Information and Indications
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information Important Prescribing Information

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

  1. Jaffe GJ, Kaiser PK, Thompson D. Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology. 2016;123(9):1856-1864.